Date: 2011-07-25
Type of information:
phase: preclinical
Announcement: results
Company: Evolva (Switzerland)
Product: EV-077
Action mechanism: EV-077 is an oral thromboxane receptor antagonist and thromboxane synthase inhibitor and belongs to a new structural class. Preclinical and early clinical studies indicate the compound has potential as an inhibitor of the effect of isoprostanes and prostanoids on the thromboxane prostanoid receptor.
Disease: complications of diabetes
Therapeutic area: Metabolic diseases
Country:
Trial
details: The aim of the presented study was to investigate the in vitro effect of EV-077 on platelet aggregation of patients with type 2 diabetes mellitus (DM) and coronary artery disease (CAD). The study was conducted on blood samples taken from 47 patients with type 2 DM and CAD on chronic daily treatment with 100mg aspirin.
Latest
news: Evolva, which is developing novel medicines and nutritional ingredients through synthetic biology, announced that data on its lead drug candidate EV-077 were presented in an oral presentation at the XXIII Congress of the International Society on Thrombosis and Haemostasis (ISTH), taking place in Kyoto, Japan. The data demonstrate that aspirin did not completely inhibit platelet aggregation in whole blood of patients with type 2 DM and CAD. The residual aggregation could be caused by thromboxane A2 and/or isoprostanes produced by leukocytes. EV-077 almost completely abolished arachidonic acid-induced platelet aggregation in whole blood of aspirin-treated patients, suggesting it might potentiate the in vivo anti-thrombotic efficacy of aspirin in type 2 diabetics with CAD. It is estimated that between 10 million and 20 million people in the developed world suffer from this condition.
The data suggest that EV-077 might potentiate the in vivo anti-thrombotic efficacy of aspirin in type 2 diabetics with coronary artery disease. The oral presentation was delivered by Dr. Kjell Sakariassen, a prominent expert in this field and member of Evolva’s Clinical Advisory Board.
